Does Erdafitinib Show Clinical Benefit in Locally Advanced or Metastatic Urothelial Carcinoma?

Erdafitinib is a tyrosine kinase inhibitor of fibroblast growth factor receptor 1 through 4 and was approved by the US Food and Drug Administration earlier this year as a second-line treatment for patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 or FGFR2 genetic alterations.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Source Type: news